2025-04-07 10:23:44,560 - implementations.XMODE.core.pipeline - DEBUG - Question: What is the mechanism of action for Cetuximab and which receptor does it target?
2025-04-07 10:23:44,899 - urllib3.connectionpool - DEBUG - Starting new HTTPS connection (1): api.smith.langchain.com:443
2025-04-07 10:23:44,971 - urllib3.connectionpool - DEBUG - https://api.smith.langchain.com:443 "GET /info HTTP/1.1" 200 672
2025-04-07 10:23:44,990 - openai._base_client - DEBUG - Request options: {'method': 'post', 'url': '/chat/completions', 'files': None, 'json_data': {'messages': [{'content': "Given a user question, a database schema and tools descriptions, analyze the question to identify and break it down into relevant sub-questions. \n            Determine which tools (e.g., text2SQL, data_preparation, plotting) are appropriate for answering each sub-question based on the available database information and tools.\n            Decompose the user question into sub_questions that capture all elements of the question's intent. This includes identifying the main objective, relevant sub-questions, necessary background information, assumptions, and any secondary requirements. \n            Ensure that no part of the original question's intent is omitted, and create a list of individual steps to answer the question fully and accurately using tools. \n            You may need to use one tool multiple times to answer to the original question.\n            First, you should begin by thoroughly analyzing the user's main question. It's important to understand the key components and objectives within the query.\n            Next, you must review the provided database schema. This involves examining the tables, fields, and relationships within the database to identify which parts of the schema are relevant to the user's question, and create text2SQL sub-questions.\n            For each sub-question, provide all the required information that may required in other tasks. In order to find this information look at the user question and the database inforamtion.\n            Ensure you include all necessary information, including columns used for filtering in the retrieve part of the database related task (i.e. Text2SQL), especially when the user question involves plotting or data exploration.\n            Each sub-question or step should focus exclusively on a single task.\n            In cases where the user's question involves data that is not directly available in the database schema —such as when there is no corresponding table or column for the required information or image analysis— you must consider the need for image analysis using the image_analysis tools. \n            For instance, if the question involves comparision of image, or asking for specific objects or a object, concepts or a concepts which is not found in the database schema, you must retrieve the `imag_path` and call image analysis task, (e.g, which image depicts <X>).\n            The database does not contain any information about what is or are depicted in a painting, to discover that you should include image analysis task.\n            This ensures we can address parts of the question that rely on visual data.\n            Always include data_preparation task to provide response to user questions in a proper way.\n            In case the question asked for plotting, you must include first data_preparation and then the data_plotting tools.\n            With a clear understanding of the question and the database schema, you can now break down the main question into smaller, more manageable sub-questions. \n            These sub-questions should each target a specific aspect of the main question. \n            After identifying the sub-questions, you should determine the most appropriate tools to answer each one. Depending on the nature of the sub-questions, we might use a variety of tools.\n            Each sub-question should be a textual question. Dont generate a code as a sub-question.\n            In any database retreival task, retieve any other columns that may requir for next tasks, especially when the user question involves plotting or data exploration.\n            Create a plan to solve it with the utmost parallelizability. \n            Each plan should comprise an action from the following  4 types:\n        1. text2SQL(problem: str, context: Optional[Union[str,list[str]]])-->str\nThe input for this tools should be `problem` as a textual question\n - You can optionally provide a list of strings as `context` to help the agent solve the problem. If there are multiple contexts you need to answer the question, you can provide them as a list of strings.\nIn the 'context' you could add any other information that you think is required to generate te SQL code. It can be the information from previous taks.\nThis tools is able to translate the question to the SQL code considering the database information.\nThe SQL code can be executed using sqlite3 library.\nUse the output of running generated SQL code to answer the question.\n\n2. data_preparation (question:str, context: Union[str, List[str],dict])-> str\n This tools is a data preparation task. For given data and question, it porcess the data and prepare the proper data structure for a request. \n - Minimize the number of `data_preparation` actions as much as possible. if you want this tools does its job properly, you should include all required information from the user query in previous tasks.\n\n3. data_plotting (question:str, context: Union[str, List[str],dict])-> str\n This tools is a data plotting task. For given data and a question, it analysis the data and plot a proper chart to answer a user query. \n - Minimize the number of `data_plotting` actions as much as possible. if you want this tools does its job properly, you should include all required information from the user query in previous tasks.\n\n        4. \n        join(): Collects and combines results from prior actions.\n\n        - An LLM agent is called upon invoking join() to either finalize the user query or wait until the plans are executed.\n        - join should always be the last action in the plan, and will be called in two scenarios:\n        (a) if the answer can be determined by gathering the outputs from tasks to generate the final response.\n        (b) if the answer cannot be determined in the planning phase before you execute the plans. Guidelines:\n        - Each action described above contains input/output types and description.\n        - You must strictly adhere to the input and output types for each action.\n        - The action descriptions contain the guidelines. You MUST strictly follow those guidelines when you use the actions.\n        - Each action in the plan should strictly be one of the above types. Follow the Python conventions for each action.\n        - Each action MUST have a unique ID, which is strictly increasing.\n        - Inputs for actions can either be constants or outputs from preceding actions. In the latter case, use the format $id to denote the ID of the previous action whose output will be the input.\n        - If there is an input from from preceding actions, always point its id as `$id` in the context of the action/\n        - Always call join as the last action in the plan. Say '<END_OF_PLAN>' after you call join\n        - Ensure the plan maximizes parallelizability.\n        - Only use the provided action types. If a query cannot be addressed using these, invoke the join action for the next steps.\n        - Never introduce new actions other than the ones provided.", 'role': 'system'}, {'content': "[HumanMessage(content='What is the mechanism of action for Cetuximab and which receptor does it target?', additional_kwargs={}, response_metadata={}, id='2f199225-4621-4caf-a8fa-27a519ef417b')]", 'role': 'user'}, {'content': 'Remember, ONLY respond with the task list in the correct format! E.g.:\nidx. tool(arg_name=args)', 'role': 'assistant'}], 'model': 'gpt-4o', 'stream': True, 'temperature': 0.0}}
2025-04-07 10:23:44,991 - openai._base_client - DEBUG - Sending HTTP Request: POST https://api.openai.com/v1/chat/completions
2025-04-07 10:23:44,991 - httpcore.connection - DEBUG - connect_tcp.started host='api.openai.com' port=443 local_address=None timeout=None socket_options=None
2025-04-07 10:23:45,014 - httpcore.connection - DEBUG - connect_tcp.complete return_value=<httpcore._backends.sync.SyncStream object at 0x16f999fc0>
2025-04-07 10:23:45,014 - httpcore.connection - DEBUG - start_tls.started ssl_context=<ssl.SSLContext object at 0x2a444d9c0> server_hostname='api.openai.com' timeout=None
2025-04-07 10:23:45,029 - httpcore.connection - DEBUG - start_tls.complete return_value=<httpcore._backends.sync.SyncStream object at 0x16f999e10>
2025-04-07 10:23:45,029 - httpcore.http11 - DEBUG - send_request_headers.started request=<Request [b'POST']>
2025-04-07 10:23:45,030 - httpcore.http11 - DEBUG - send_request_headers.complete
2025-04-07 10:23:45,030 - httpcore.http11 - DEBUG - send_request_body.started request=<Request [b'POST']>
2025-04-07 10:23:45,030 - httpcore.http11 - DEBUG - send_request_body.complete
2025-04-07 10:23:45,030 - httpcore.http11 - DEBUG - receive_response_headers.started request=<Request [b'POST']>
2025-04-07 10:23:45,110 - urllib3.connectionpool - DEBUG - https://api.smith.langchain.com:443 "POST /runs/multipart HTTP/1.1" 202 34
2025-04-07 10:23:45,372 - httpcore.http11 - DEBUG - receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Date', b'Mon, 07 Apr 2025 14:23:45 GMT'), (b'Content-Type', b'text/event-stream; charset=utf-8'), (b'Transfer-Encoding', b'chunked'), (b'Connection', b'keep-alive'), (b'access-control-expose-headers', b'X-Request-ID'), (b'openai-organization', b'user-c4kmud4pram6lu62sxpadvux'), (b'openai-processing-ms', b'229'), (b'openai-version', b'2020-10-01'), (b'x-ratelimit-limit-requests', b'5000'), (b'x-ratelimit-limit-tokens', b'800000'), (b'x-ratelimit-remaining-requests', b'4999'), (b'x-ratelimit-remaining-tokens', b'798177'), (b'x-ratelimit-reset-requests', b'12ms'), (b'x-ratelimit-reset-tokens', b'136ms'), (b'x-request-id', b'req_92331a1fd3e05dbab0917dfdfbae8381'), (b'strict-transport-security', b'max-age=31536000; includeSubDomains; preload'), (b'cf-cache-status', b'DYNAMIC'), (b'Set-Cookie', b'__cf_bm=WkzxWm4QHib1gAlohnwfQ3ehBoZZiD2Vnzgd63HEcpI-1744035825-1.0.1.1-EsatzyLualP7pOzjjNsj5lrFmSeAwaHjqmq9Pf.qPVd1D0_YcHXmsZOfPGPJrnRLmIKZKiomx2h5GF_jDMhnkiFSoatpN23wxGQUKgdsQeE; path=/; expires=Mon, 07-Apr-25 14:53:45 GMT; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), (b'X-Content-Type-Options', b'nosniff'), (b'Set-Cookie', b'_cfuvid=.TI3lFRyReB7GR3TynirNhAkUnqxKnOA3QxO2eEyfCE-1744035825409-0.0.1.1-604800000; path=/; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), (b'Server', b'cloudflare'), (b'CF-RAY', b'92ca2f42bd84a1fe-YYZ'), (b'alt-svc', b'h3=":443"; ma=86400')])
2025-04-07 10:23:45,373 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2025-04-07 10:23:45,373 - openai._base_client - DEBUG - HTTP Response: POST https://api.openai.com/v1/chat/completions "200 OK" Headers([('date', 'Mon, 07 Apr 2025 14:23:45 GMT'), ('content-type', 'text/event-stream; charset=utf-8'), ('transfer-encoding', 'chunked'), ('connection', 'keep-alive'), ('access-control-expose-headers', 'X-Request-ID'), ('openai-organization', 'user-c4kmud4pram6lu62sxpadvux'), ('openai-processing-ms', '229'), ('openai-version', '2020-10-01'), ('x-ratelimit-limit-requests', '5000'), ('x-ratelimit-limit-tokens', '800000'), ('x-ratelimit-remaining-requests', '4999'), ('x-ratelimit-remaining-tokens', '798177'), ('x-ratelimit-reset-requests', '12ms'), ('x-ratelimit-reset-tokens', '136ms'), ('x-request-id', 'req_92331a1fd3e05dbab0917dfdfbae8381'), ('strict-transport-security', 'max-age=31536000; includeSubDomains; preload'), ('cf-cache-status', 'DYNAMIC'), ('set-cookie', '__cf_bm=WkzxWm4QHib1gAlohnwfQ3ehBoZZiD2Vnzgd63HEcpI-1744035825-1.0.1.1-EsatzyLualP7pOzjjNsj5lrFmSeAwaHjqmq9Pf.qPVd1D0_YcHXmsZOfPGPJrnRLmIKZKiomx2h5GF_jDMhnkiFSoatpN23wxGQUKgdsQeE; path=/; expires=Mon, 07-Apr-25 14:53:45 GMT; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), ('x-content-type-options', 'nosniff'), ('set-cookie', '_cfuvid=.TI3lFRyReB7GR3TynirNhAkUnqxKnOA3QxO2eEyfCE-1744035825409-0.0.1.1-604800000; path=/; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), ('server', 'cloudflare'), ('cf-ray', '92ca2f42bd84a1fe-YYZ'), ('alt-svc', 'h3=":443"; ma=86400')])
2025-04-07 10:23:45,374 - openai._base_client - DEBUG - request_id: req_92331a1fd3e05dbab0917dfdfbae8381
2025-04-07 10:23:45,374 - httpcore.http11 - DEBUG - receive_response_body.started request=<Request [b'POST']>
2025-04-07 10:23:45,634 - langsmith._internal._serde - DEBUG - Failed to use model_dump to serialize <class 'langchain_core.tools.structured.StructuredTool'> to JSON: PydanticSerializationError(Unable to serialize unknown type: <class 'pydantic._internal._model_construction.ModelMetaclass'>)
2025-04-07 10:23:45,650 - openai._base_client - DEBUG - Request options: {'method': 'post', 'url': '/chat/completions', 'files': None, 'json_data': {'messages': [{'content': "  \nYou are a database expert. Generate a SQL query given the following user question, database information and other context that you receive.\nYou should analyse the question, context and the database schema and come with the executabel sqlite3 query. \nProvide all the required information in the SQL code to answer the original user question that may required in other tasks utilizing the relevant database schema.\nEnsure you include all necessary information, including columns used for filtering, especially when the task involves plotting or data exploration.\nThis must be taken into account when performing any time-based data queries or analyses.\nif the question asks for information that is not found in the database schema, you must retrieve the `ima_path` for image analysis task.\nTranslate a text question into a SQL query that can be executed on the SQLite database.\nList of Businnes Roles to take into account during the translation task:\n1- To calculate century from inception field use : (CAST(strftime('%Y', inception) AS INTEGER) - 1) / 100 + 1\n....\n", 'role': 'system'}, {'content': 'What is the mechanism of action for Cetuximab and which receptor does it target?', 'role': 'user'}, {'content': '\nCREATE TABLE drugbank_carriers (\n\tid TEXT, \n\tname TEXT, \n\torganism TEXT, \n\tknown_action TEXT, \n\tposition REAL, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_carriers table:\nid\tname\torganism\tknown_action\tposition\tparent_key\nBE0000537\tThyroxine-binding globulin\tHumans\tno\t1.0\tDB00023\nBE0000537\tThyroxine-binding globulin\tHumans\tno\t1.0\tDB00059\nBE0000530\tSerum albumin\tHumans\tunknown\t5.0\tDB00070\nBE0000530\tSerum albumin\tHumans\tunknown\t4.0\tDB00104\nBE0000530\tSerum albumin\tHumans\tunknown\t30.0\tDB00126\n*/\n\n\nCREATE TABLE drugbank_carriers_actions (\n\taction TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_carriers_actions table:\naction\tparent_id\ninhibitor\tBE0000537\ninhibitor\tBE0000530\nbinder\tBE0000530\nbinder\tBE0001141\nagonist\tBE0001821\n*/\n\n\nCREATE TABLE drugbank_carriers_polypeptides (\n\tid TEXT, \n\tsource TEXT, \n\tname TEXT, \n\tgeneral_function TEXT, \n\tspecific_function TEXT, \n\tgene_name TEXT, \n\tlocus TEXT, \n\tcellular_location TEXT, \n\ttransmembrane_regions TEXT, \n\tsignal_regions TEXT, \n\ttheoretical_pi REAL, \n\tmolecular_weight REAL, \n\tchromosome_location REAL, \n\torganism TEXT, \n\torganism_ncbi_taxonomy_id INTEGER, \n\tamino_acid_sequence TEXT, \n\tamino_acid_format TEXT, \n\tgene_sequence TEXT, \n\tgene_format TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_carriers_polypeptides table:\nid\tsource\tname\tgeneral_function\tspecific_function\tgene_name\tlocus\tcellular_location\ttransmembrane_regions\tsignal_regions\ttheoretical_pi\tmolecular_weight\tchromosome_location\torganism\torganism_ncbi_taxonomy_id\tamino_acid_sequence\tamino_acid_format\tgene_sequence\tgene_format\tparent_id\nP05543\tSwiss-Prot\tThyroxine-binding globulin\tSerine-type endopeptidase inhibitor activity\tMajor thyroid hormone transport protein in serum.\tSERPINA7\tXq22.2\tSecreted\tNone\t1-20\t6.27\t46324.12\tNone\tHumans\t9606\t>lcl|BSEQ0016123|Thyroxine-binding globulin\nMSPFLYLVLLVLGLHATIHCASPEGKVTACHSSQPNATLYKMSSINADFAFNLYRR\tFASTA\t>lcl|BSEQ0016124|Thyroxine-binding globulin (SERPINA7)\nATGTCACCATTCCTGTATCTGGTTCTCTTGGTACTTGGGCTTCAT\tFASTA\tBE0000537\nP02768\tSwiss-Prot\tSerum albumin\tToxic substance binding\tSerum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+\tALB\t4q11-q13\tSecreted\tNone\t1-18\t6.21\t69365.94\tNone\tHumans\t9606\t>lcl|BSEQ0001058|Serum albumin\nMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF\nEDHVKLVN\tFASTA\t>lcl|BSEQ0010372|Serum albumin (ALB)\nATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT\nGT\tFASTA\tBE0000530\nO15540\tSwiss-Prot\tFatty acid-binding protein, brain\tTransporter activity\tB-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morp\tFABP7\t6q22-q23\tCytoplasm\tNone\tNone\t5.25\t14888.855\tNone\tHumans\t9606\t>lcl|BSEQ0003608|Fatty acid-binding protein, brain\nMVEAFCATWKLTNSQNFDEYMKALGVGFATRQVGNVTKPTVIISQEGDK\tFASTA\t>lcl|BSEQ0021304|Fatty acid-binding protein, brain (FABP7)\nATGGTGGAGGCTTTCTGTGCTACCTGGAAGCTGACCAACAG\tFASTA\tBE0001821\nP02774\tSwiss-Prot\tVitamin D-binding protein\tVitamin transporter activity\tInvolved in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the\tGC\t4q12-q13\tSecreted\tNone\t1-16\t5.21\t52963.025\tNone\tHumans\t9606\t>lcl|BSEQ0002269|Vitamin D-binding protein\nMKRVLVLLLAVAFGHALERGRDYEKNKVCKEFSHLGKEDFTSLSLVLYSRKFPSGTF\tFASTA\t>lcl|BSEQ0010798|Vitamin D-binding protein (GC)\nATGAAGAGGGTCCTGGTACTACTGCTTGCTGTGGCATTTGGACATGCTTTAG\tFASTA\tBE0001141\nP82980\tSwiss-Prot\tRetinol-binding protein 5\tTransporter activity\tIntracellular transport of retinol.\tRBP5\t12p13.31\tCytoplasm\tNone\tNone\t6.51\t15931.17\tNone\tHumans\t9606\t>lcl|BSEQ0010475|Retinol-binding protein 5\nMPPNLTGYYRFVSQKNMEDYLQALNISLAVRKIALLLKPDKEIEHQGNHMTVRTLST\tFASTA\t>lcl|BSEQ0010476|Retinol-binding protein 5 (RBP5)\nATGCCTCCCAACCTCACTGGCTACTACCGCTTTGTCTCGCAGAAGAACAT\tFASTA\tBE0000682\n*/\n\n\nCREATE TABLE drugbank_carriers_polypeptides_ext_id (\n\tresource TEXT, \n\tidentifier TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_carriers_polypeptides_ext_id table:\nresource\tidentifier\tparent_key\nHUGO Gene Nomenclature Committee (HGNC)\tHGNC:11583\tBE0000537\nGenAtlas\tSERPINA7\tBE0000537\nGenBank Gene Database\tM14091\tBE0000537\nGenBank Protein Database\t338697\tBE0000537\nUniProtKB\tP05543\tBE0000537\n*/\n\n\nCREATE TABLE drugbank_carriers_polypeptides_go (\n\tcategory TEXT, \n\tdescription TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_carriers_polypeptides_go table:\ncategory\tdescription\tparent_key\ncomponent\textracellular exosome\tBE0000537\ncomponent\textracellular region\tBE0000537\ncomponent\textracellular space\tBE0000537\nfunction\thormone binding\tBE0000537\nfunction\tserine-type endopeptidase inhibitor activity\tBE0000537\n*/\n\n\nCREATE TABLE drugbank_carriers_polypeptides_pfams (\n\tidentifier TEXT, \n\tname TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_carriers_polypeptides_pfams table:\nidentifier\tname\tparent_key\nPF00079\tSerpin\tBE0000537\nPF00273\tSerum_albumin\tBE0000530\nPF00061\tLipocalin\tBE0001821\nPF00273\tSerum_albumin\tBE0001141\nPF09164\tVitD-bind_III\tBE0001141\n*/\n\n\nCREATE TABLE drugbank_carriers_polypeptides_syn (\n\ttext TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_carriers_polypeptides_syn table:\ntext\tparent_key\nSerpin A7\tBE0000537\nT4-binding globulin\tBE0000537\nTBG\tBE0000537\nSerum albumin precursor\tBE0000530\nB-FABP\tBE0001821\n*/\n\n\nCREATE TABLE drugbank_drug (\n\tprimary_key TEXT, \n\tother_keys TEXT, \n\ttype TEXT, \n\tcreated TEXT, \n\tupdated TEXT, \n\tname TEXT, \n\tdescription TEXT, \n\tcas_number TEXT, \n\tunii TEXT, \n\taverage_mass REAL, \n\tmonoisotopic_mass REAL, \n\tstate TEXT, \n\tsynthesis_reference TEXT, \n\tfda_label TEXT, \n\tmsds TEXT\n)\n\n/*\n5 rows from drugbank_drug table:\nprimary_key\tother_keys\ttype\tcreated\tupdated\tname\tdescription\tcas_number\tunii\taverage_mass\tmonoisotopic_mass\tstate\tsynthesis_reference\tfda_label\tmsds\nDB00001\tBTD00024;BIOD00024\tbiotech\t2005-06-13\t2020-06-12\tLepirudin\tLepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N\t138068-37-8\tY43GF64R34\tNone\tNone\tliquid\tNone\t//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00001.pdf?1265924858\t//s3-us-west-2.amazonaws.com/drugbank/msds/DB00001.pdf?1368416245\nDB00002\tBTD00071;BIOD00071\tbiotech\t2005-06-13\t2020-07-01\tCetuximab\tCetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (varia\t205923-56-4\tPQX0D8J21J\tNone\tNone\tliquid\tNone\t//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813\t//s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933\nDB00003\tBTD00001;BIOD00001\tbiotech\t2005-06-13\t2020-07-01\tDornase alfa\tDornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in\t143831-71-4\t953A26OA1Y\tNone\tNone\tliquid\tNone\t//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221\t//s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694\nDB00004\tBTD00084;BIOD00084\tbiotech\t2005-06-13\t2020-06-12\tDenileukin diftitox\tA recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxi\t173146-27-5\t25E79B5CTM\tNone\tNone\tliquid\tNone\t//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00004.pdf?1265922800\tNone\nDB00005\tBTD00052;BIOD00052\tbiotech\t2005-06-13\t2020-07-01\tEtanercept\tDimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kiloda\t185243-69-0\tOP401G7OJC\tNone\tNone\tliquid\tTimothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, "Crystals of etanercept \tNone\tNone\n*/\n\n\nCREATE TABLE drugbank_drug_affected_organisms (\n\taffected_organism TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_affected_organisms table:\naffected_organism\tdrugbank_id\nHumans and other mammals\tDB00001\nHumans and other mammals\tDB00002\nHumans and other mammals\tDB00003\nHumans and other mammals\tDB00004\nHumans and other mammals\tDB00005\n*/\n\n\nCREATE TABLE drugbank_drug_ahfs_codes (\n\tahfs_code TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_ahfs_codes table:\nahfs_code\tdrugbank_id\n10:00.00\tDB00002\n44:00.00\tDB00003\n92:36.00\tDB00005\n20:12.04.12\tDB00006\n10:00.00\tDB00007\n*/\n\n\nCREATE TABLE drugbank_drug_atc_codes (\n\tatc_code TEXT, \n\tlevel_1 TEXT, \n\tcode_1 TEXT, \n\tlevel_2 TEXT, \n\tcode_2 TEXT, \n\tlevel_3 TEXT, \n\tcode_3 TEXT, \n\tlevel_4 TEXT, \n\tcode_4 TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_atc_codes table:\natc_code\tlevel_1\tcode_1\tlevel_2\tcode_2\tlevel_3\tcode_3\tlevel_4\tcode_4\tdrugbank_id\nB01AE02\tDirect thrombin inhibitors\tB01AE\tANTITHROMBOTIC AGENTS\tB01A\tANTITHROMBOTIC AGENTS\tB01\tBLOOD AND BLOOD FORMING ORGANS\tB\tDB00001\nL01XC06\tMonoclonal antibodies\tL01XC\tOTHER ANTINEOPLASTIC AGENTS\tL01X\tANTINEOPLASTIC AGENTS\tL01\tANTINEOPLASTIC AND IMMUNOMODULATING AGENTS\tL\tDB00002\nR05CB13\tMucolytics\tR05CB\tEXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS\tR05C\tCOUGH AND COLD PREPARATIONS\tR05\tRESPIRATORY SYSTEM\tR\tDB00003\nL01XX29\tOther antineoplastic agents\tL01XX\tOTHER ANTINEOPLASTIC AGENTS\tL01X\tANTINEOPLASTIC AGENTS\tL01\tANTINEOPLASTIC AND IMMUNOMODULATING AGENTS\tL\tDB00004\nL04AB01\tTumor necrosis factor alpha (TNF-α) inhibitors\tL04AB\tIMMUNOSUPPRESSANTS\tL04A\tIMMUNOSUPPRESSANTS\tL04\tANTINEOPLASTIC AND IMMUNOMODULATING AGENTS\tL\tDB00005\n*/\n\n\nCREATE TABLE drugbank_drug_calculated_properties (\n\tkind TEXT, \n\tvalue TEXT, \n\tsource TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_calculated_properties table:\nkind\tvalue\tsource\tparent_key\nlogP\t-0.76\tALOGPS\tDB00006\nlogS\t-4.7\tALOGPS\tDB00006\nWater Solubility\t4.64e-02 g/l\tALOGPS\tDB00006\nlogP\t-14\tChemAxon\tDB00006\nIUPAC Name\t(4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-(2-{2-[2-(2-{[(2S)-1-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-phen\tChemAxon\tDB00006\n*/\n\n\nCREATE TABLE drugbank_drug_carriers_articles (\n\tref_id TEXT, \n\tpubmed_id REAL, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_carriers_articles table:\nref_id\tpubmed_id\tcitation\tparent_key\nA11627\t10036158.0\tMaingonnat C, Victor R, Bertrand P, Courel MN, Maunoury R, Delpech B: Activation and inhibition of h\tBE0000530\nA11628\t10466114.0\tParameswaran S, Brown LV, Ibbott GS, Lai-Fook SJ: Effect of concentration and hyaluronidase on album\tBE0000530\nA192021\t12090938.0\tLozinsky E, Novoselsky A, Glaser R, Shames AI, Likhtenshtein GI, Meyerstein D: Effect of ionic stren\tBE0000530\nA192024\t6735617.0\tOelrichs BA, Kratzing CC, Kelly JD, Winzor DJ: The binding of ascorbate to bovine serum albumin. Int\tBE0000530\nA13643\t10854433.0\tBalendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, Lim K, Godbout R, Spener F, Sacchettini J\tBE0001821\n*/\n\n\nCREATE TABLE drugbank_drug_carriers_attachments (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_carriers_attachments table:\nref_id\ttitle\turl\tparent_key\nF3799\tCYTOMEL (liothyronine) FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/799/original/fda.pdf?15518\tBE0000537\nF3799\tCYTOMEL (liothyronine) FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/799/original/fda.pdf?15518\tBE0000537\nF4127\tMADELINE (desogestrel and ethinyl estradiol) Australian monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/127/original/1.pdf?1553644\tBE0000530\nF4127\tMADELINE (desogestrel and ethinyl estradiol) Australian monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/127/original/1.pdf?1553644\tBE0000685\nF3799\tCYTOMEL (liothyronine) FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/799/original/fda.pdf?15518\tBE0000537\n*/\n\n\nCREATE TABLE drugbank_drug_carriers_links (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_carriers_links table:\nref_id\ttitle\turl\tparent_key\nL14513\tProduct monograph: Sandostatin (octreotide acetate) injection\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19667scm044_Sandostatin_lbl.pdf\tBE0000530\nL5473\tAustralian Assessment Report\thttps://www.tga.gov.au/sites/default/files/auspar-ranolazine-180220.pdf\tBE0000925\nL7342\tFDA Approved Drug Products: Geodon (ziprasidone HCl)\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020825s059,020919s047lbl.pdf\tBE0000925\nL7763\tEUTHYROX (levothyroxine sodium) tablets, for oral use - FDA Label\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021292s004,021292s005,021292s006lbl.pdf\tBE0000537\nL10544\tFDA label, topiramate\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf\tBE0000530\n*/\n\n\nCREATE TABLE drugbank_drug_carriers_textbooks (\n\tref_id TEXT, \n\tisbn TEXT, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_carriers_textbooks table:\nref_id\tisbn\tcitation\tparent_key\nT592\tNone\tSpeeckaert M., Speeckaert R., Geel N. and Delanghe J. (2014). Advances in Clinical Chemistry. Elsevi\tBE0001141\nT445\t978-0-8261-2858-4\tHale T. and Rowe H. (2017). MEdications & mothers\' milk (17th ed.). Springer publishing company.\tBE0000530\nT55\tNone\tZaragoza Dorwald F. (2012). Lead optimization for medicinal chemists. Wiley-VCH.\tBE0000530\nT55\tNone\tZaragoza Dorwald F. (2012). Lead optimization for medicinal chemists. Wiley-VCH.\tBE0000685\nT116\t978-1-25-958473-2\tSchimmer B, Funder J (2018). 46. In Goodman & Gilman\'s: The Pharmacological Basis of Therapeutics (1\tBE0000209\n*/\n\n\nCREATE TABLE drugbank_drug_categories (\n\tcategory TEXT, \n\tmesh_id TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_categories table:\ncategory\tmesh_id\tparent_key\nAmino Acids, Peptides, and Proteins\tD000602\tDB00001\nAnticoagulants\tD000925\tDB00001\nAntithrombin Proteins\tD058833\tDB00001\nAntithrombins\tD000991\tDB00001\nBlood and Blood Forming Organs\tNone\tDB00001\n*/\n\n\nCREATE TABLE drugbank_drug_classifications (\n\tdescription TEXT, \n\tdirect_parent TEXT, \n\tkingdom TEXT, \n\tsuperclass TEXT, \n\tclass TEXT, \n\tsubclass TEXT, \n\talternative_parents TEXT, \n\tsubstituents TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_classifications table:\ndescription\tdirect_parent\tkingdom\tsuperclass\tclass\tsubclass\talternative_parents\tsubstituents\tdrugbank_id\nNone\tPeptides\tOrganic Compounds\tOrganic Acids\tCarboxylic Acids and Derivatives\tAmino Acids, Peptides, and Analogues\tNone\tNone\tDB00001\nNone\tPeptides\tOrganic Compounds\tOrganic Acids\tCarboxylic Acids and Derivatives\tAmino Acids, Peptides, and Analogues\tNone\tNone\tDB00002\nNone\tPeptides\tOrganic Compounds\tOrganic Acids\tCarboxylic Acids and Derivatives\tAmino Acids, Peptides, and Analogues\tNone\tNone\tDB00003\nNone\tPeptides\tOrganic Compounds\tOrganic Acids\tCarboxylic Acids and Derivatives\tAmino Acids, Peptides, and Analogues\tNone\tNone\tDB00004\nNone\tPeptides\tOrganic Compounds\tOrganic Acids\tCarboxylic Acids and Derivatives\tAmino Acids, Peptides, and Analogues\tNone\tNone\tDB00005\n*/\n\n\nCREATE TABLE drugbank_drug_dosages (\n\tform TEXT, \n\troute TEXT, \n\tstrength TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_dosages table:\nform\troute\tstrength\tparent_key\nInjection, solution, concentrate\tIntravenous\t20 mg\tDB00001\nInjection, solution, concentrate\tIntravenous\t50 mg\tDB00001\nPowder\tIntravenous\t50 mg/1mL\tDB00001\nPowder, for solution\tIntravenous\t50 mg\tDB00001\nInjection, solution\tIntravenous\t5 mg/ml\tDB00002\n*/\n\n\nCREATE TABLE drugbank_drug_enzymes_articles (\n\tref_id TEXT, \n\tpubmed_id REAL, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_enzymes_articles table:\nref_id\tpubmed_id\tcitation\tparent_key\nA17596\t18701766.0\tRudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Bal\tBE0001075\nA39126\t11910269.0\tBegre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann\tBE0002433\nA181307\t9064483.0\tDelaporte E, Renton KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcri\tBE0002433\nA191940\t12195704.0\tAndolfo A, English WR, Resnati M, Murphy G, Blasi F, Sidenius N: Metalloproteases cleave the urokina\tBE0001198\nA181307\t9064483.0\tDelaporte E, Renton KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcri\tBE0002433\n*/\n\n\nCREATE TABLE drugbank_drug_enzymes_attachments (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_enzymes_attachments table:\nref_id\ttitle\turl\tparent_key\nF1718\tPeg-interferon FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/718/original/peg.pdf?15384\tBE0002433\nF1719\tPeg-interferon alfa-2b FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/719/original/Peg_interfero\tBE0002433\nF1814\tSylatron FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/814/original/103949s5153lb\tBE0002793\nF1722\tPEG-Intron package insert\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/722/original/PEG-Intron_%2\tBE0002433\nF1694\tFluvoxamine FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/694/original/Fluvoxamine_F\tBE0002433\n*/\n\n\nCREATE TABLE drugbank_drug_enzymes_links (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_enzymes_links table:\nref_id\ttitle\turl\tparent_key\nL4626\tAids info document\thttps://aidsinfo.nih.gov/drugs/487/peginterferon-alfa-2b--hcv/136/professional\tBE0002793\nL5707\tUniprot P16519\thttps://www.uniprot.org/uniprot/P16519\tBE0002124\nL5710\tUniprot P29120\thttps://www.uniprot.org/uniprot/P29120\tBE0002125\nL162\tFlockhart Table of Drug Interactions\thttps://drug-interactions.medicine.iu.edu/Main-Table.aspx\tBE0002362\nL3734\tNeoral (Cyclosporine) FDA Label\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf\tBE0002362\n*/\n\n\nCREATE TABLE drugbank_drug_enzymes_textbooks (\n\tref_id TEXT, \n\tisbn TEXT, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_enzymes_textbooks table:\nref_id\tisbn\tcitation\tparent_key\nT312\tNone\tLitt J. (2016). Litt\'s Drug eruption & reaction manual (22nd ed.). CRC Press LLc.\tBE0002638\nT229\t1-894402-22-7\tClin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for\tBE0002638\nT229\t1-894402-22-7\t`Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference fo\tBE0002793\nT306\t978-0-803-669468\tVallerand A. and Sanoski C. (2017). David\'s Canadian Drug Guide for Nurses (16th ed.). FA Davis Comp\tBE0002638\nT243\t978-1-4614-7495-1\tMarcucci C., Hutchens M., Wittwer E., Weingarten T., Sprung J., Nicholson W., Lalwani K., Metro D., \tBE0002638\n*/\n\n\nCREATE TABLE drugbank_drug_experimental_properties (\n\tkind TEXT, \n\tvalue TEXT, \n\tsource TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_experimental_properties table:\nkind\tvalue\tsource\tparent_key\nMelting Point\t65 °C\tOtto, A. & Seckler, R. Eur. J. Biochem. 202:67-73 (1991)\tDB00001\nHydrophobicity\t-0.777\tNone\tDB00001\nIsoelectric Point\t4.04\tNone\tDB00001\nMolecular Weight\t6963.425\tNone\tDB00001\nMolecular Formula\tC287H440N80O110S6\tNone\tDB00001\n*/\n\n\nCREATE TABLE drugbank_drug_external_identifiers (\n\tresource TEXT, \n\tidentifier TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_external_identifiers table:\nresource\tidentifier\tparent_key\nDrugs Product Database (DPD)\t11916\tDB00001\nPubChem Substance\t46507011\tDB00001\nKEGG Drug\tD06880\tDB00001\nPharmGKB\tPA450195\tDB00001\nUniProtKB\tP01050\tDB00001\n*/\n\n\nCREATE TABLE drugbank_drug_external_links (\n\tresource TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_external_links table:\nresource\turl\tparent_key\nRxList\thttp://www.rxlist.com/cgi/generic/lepirudin.htm\tDB00001\nDrugs.com\thttp://www.drugs.com/cdi/lepirudin.html\tDB00001\nRxList\thttp://www.rxlist.com/cgi/generic3/erbitux.htm\tDB00002\nDrugs.com\thttp://www.drugs.com/cdi/cetuximab.html\tDB00002\nRxList\thttp://www.rxlist.com/cgi/generic/pulmozyme.htm\tDB00003\n*/\n\n\nCREATE TABLE drugbank_drug_food_interactions (\n\tfood_interaction TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_food_interactions table:\nfood_interaction\tdrugbank_id\nAvoid echinacea.\tDB00006\nAvoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include ginseng, gink\tDB00006\nDrink plenty of fluids.\tDB00008\nAvoid alcohol.\tDB00011\nAvoid alcohol. Alcohol may impair blood glucose control.\tDB00030\n*/\n\n\nCREATE TABLE drugbank_drug_groups (\n\t"group" TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_groups table:\ngroup\tdrugbank_id\napproved\tDB00001\napproved\tDB00002\napproved\tDB00003\napproved\tDB00004\ninvestigational\tDB00004\n*/\n\n\nCREATE TABLE drugbank_drug_international_brands (\n\tbrand TEXT, \n\tcompany TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_international_brands table:\nbrand\tcompany\tdrugbank_id\nViscozyme\tRoche (Chile)\tDB00003\nDavictrel\tNone\tDB00005\nTunex\tNone\tDB00005\nAngiox\tNone\tDB00006\nHirulog\tNone\tDB00006\n*/\n\n\nCREATE TABLE drugbank_drug_manufacturers (\n\tmanufacturer TEXT, \n\tgeneric INTEGER, \n\turl TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_manufacturers table:\nmanufacturer\tgeneric\turl\tdrugbank_id\nBayer healthcare pharmaceuticals inc\t0\tNone\tDB00001\nGenentech, Inc\t0\tNone\tDB00003\nAmgen Inc. + Wyeth + Takeda\t0\tNone\tDB00005\nThe medicines co\t0\tNone\tDB00006\nEmd serono inc\t0\tNone\tDB00010\n*/\n\n\nCREATE TABLE drugbank_drug_mixtures (\n\tname TEXT, \n\tingredients TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_mixtures table:\nname\tingredients\tparent_key\nRefludan\tLepirudin\tDB00001\nErbitux\tCetuximab\tDB00002\nPulmozyme\tDornase alfa\tDB00003\nPulmozyme 1mg/ml\tDornase alfa\tDB00003\nOntak\tDenileukin diftitox\tDB00004\n*/\n\n\nCREATE TABLE drugbank_drug_packagers (\n\tname TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_packagers table:\nname\turl\tparent_key\nBayer Healthcare\thttp://www.bayerhealthcare.com\tDB00001\nBerlex Labs\thttp://www.berlex.com\tDB00001\nCardinal Health\thttp://www.cardinal.com\tDB00002\nCatalent Pharma Solutions\thttp://www.catalent.com\tDB00002\nImClone Systems Inc.\thttp://www.imclone.com\tDB00002\n*/\n\n\nCREATE TABLE drugbank_drug_patents (\n\tnumber TEXT, \n\tcountry TEXT, \n\tapproved TEXT, \n\texpires TEXT, \n\tpediatric_extension INTEGER, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_patents table:\nnumber\tcountry\tapproved\texpires\tpediatric_extension\tparent_key\n5180668\tUnited States\t1993-01-19\t2010-01-19\t0\tDB00001\n1340417\tCanada\t1999-03-02\t2016-03-02\t0\tDB00002\n2184581\tCanada\t2005-02-22\t2015-02-28\t0\tDB00003\n2137237\tCanada\t2004-10-26\t2013-05-28\t0\tDB00003\n2476934\tCanada\t2009-06-16\t2023-02-27\t0\tDB00005\n*/\n\n\nCREATE TABLE drugbank_drug_pathway (\n\tsmpdb_id TEXT, \n\tname TEXT, \n\tcategory TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_pathway table:\nsmpdb_id\tname\tcategory\tparent_key\nSMP0000278\tLepirudin Action Pathway\tdrug_action\tDB00001\nSMP0000474\tCetuximab Action Pathway\tdrug_action\tDB00002\nSMP0000277\tBivalirudin Action Pathway\tdrug_action\tDB00006\nSMP0000280\tAlteplase Action Pathway\tdrug_action\tDB00009\nSMP0000284\tUrokinase Action Pathway\tdrug_action\tDB00013\n*/\n\n\nCREATE TABLE drugbank_drug_pathway_drugs (\n\tdrugbank_id TEXT, \n\tname TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_pathway_drugs table:\ndrugbank_id\tname\tparent_key\nDB00001\tLepirudin\tSMP0000278\nDB01022\tPhylloquinone\tSMP0000278\nDB01373\tCalcium\tSMP0000278\nDB00002\tCetuximab\tSMP0000474\nDB00006\tBivalirudin\tSMP0000277\n*/\n\n\nCREATE TABLE drugbank_drug_pathway_enzymes (\n\tenzyme TEXT, \n\tpathway_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_pathway_enzymes table:\nenzyme\tpathway_id\nP00734\tSMP0000278\nP00748\tSMP0000278\nP02452\tSMP0000278\nP03952\tSMP0000278\nP03951\tSMP0000278\n*/\n\n\nCREATE TABLE drugbank_drug_pdb_entries (\n\tpdb_entry TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_pdb_entries table:\npdb_entry\tdrugbank_id\n1a3g\tDB00114\n1a50\tDB00114\n1a5a\tDB00114\n1a5b\tDB00114\n1a5s\tDB00114\n*/\n\n\nCREATE TABLE drugbank_drug_pharmacology (\n\tdrugbank_id TEXT, \n\tindication TEXT, \n\tpharmacodynamics TEXT, \n\tmechanism_of_action TEXT, \n\ttoxicity TEXT, \n\tmetabolism TEXT, \n\tabsorption TEXT, \n\thalf_life TEXT, \n\tprotein_binding TEXT, \n\troute_of_elimination TEXT, \n\tvolume_of_distribution TEXT, \n\tclearance TEXT\n)\n\n/*\n5 rows from drugbank_drug_pharmacology table:\ndrugbank_id\tindication\tpharmacodynamics\tmechanism_of_action\ttoxicity\tmetabolism\tabsorption\thalf_life\tprotein_binding\troute_of_elimination\tvolume_of_distribution\tclearance\nDB00001\tFor the treatment of heparin-induced thrombocytopenia\tLepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevent\tLepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to\tIn case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increase\tLepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the par\tBioavailability is 100% following injection.\tApproximately 1.3 hours\tNone\tLepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the par\t* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]\r\n* 18.7 L [Healthy elderly subjects (n =\t* 164 ml/min [Healthy 18-60 yrs]\r\n* 139 ml/min [Healthy 65-80 yrs]\r\n* 61 ml/min [renal impaired]\r\n* \nDB00002\tCetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, m\tUsed in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth fac\tCetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr \tPulmonary Toxicity\r\n\r\nInterstitial lung disease (ILD) was reported in 3 of 633 (<0.5%) patients with\tNone\tNone\tThe mean half-life for Cetuximab is 114 hours (range 75-188 hours).\tNone\tNone\tappeared to be independent of dose and approximated the vascular space of 2-3 L/m2.\tFemale patients had 25% lower intrinsic clearance than male patients.\nDB00003\tUsed as adjunct therapy in the treatment of cystic fibrosis. \tCystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in t\tDornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic clea\tAdverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Rep\tWhile no conclusive studies have yet been published, dornase alfa is expected to be metabolized by p\tStudies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (\tNone\tNone\tNone\tIn studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. C\tStudies in rats indicate that, following aerosol administration, the disappearance half-life of dorn\nDB00004\tFor treatment of cutaneous T-cell lymphoma\tDenileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express \tDenileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subuni\tNone\tNone\tNone\t70-80 min\tNone\tNone\t* 0.06 to 0.09 L/kg\t* 0.6 - 2.0 mL/min/kg [Lymphoma]\nDB00005\tEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in a\tEtanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological proces\tThere are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton \tNone\tNone\tBioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achi\t102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults.\tNone\tNone\tNone\t* 160 +/- 80 mL/hr [RA patients]\n*/\n\n\nCREATE TABLE drugbank_drug_prices (\n\tdescription TEXT, \n\tcurrency TEXT, \n\tcost REAL, \n\tunit TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_prices table:\ndescription\tcurrency\tcost\tunit\tparent_key\nRefludan 50 mg vial\tUSD\t273.19\tvial\tDB00001\nLufyllin 200 mg tablet\tUSD\t3.21\ttablet\tDB00003\nLufyllin-gg tablet\tUSD\t3.84\ttablet\tDB00003\nLufyllin-GG 200-200 mg tablet\tUSD\t3.99\ttablet\tDB00003\nLufyllin-400 tablet\tUSD\t4.62\ttablet\tDB00003\n*/\n\n\nCREATE TABLE drugbank_drug_reactions (\n\tsequence INTEGER, \n\tleft_drugbank_id TEXT, \n\tleft_drugbank_name TEXT, \n\tright_drugbank_id TEXT, \n\tright_drugbank_name TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_reactions table:\nsequence\tleft_drugbank_id\tleft_drugbank_name\tright_drugbank_id\tright_drugbank_name\tparent_key\n1\tDB00047\tInsulin glargine\tDBMET00786\tA21-Gly-des-B30-Thr-insulin\tDB00047\n1\tDB00047\tInsulin glargine\tDBMET00787\tA21-Gly-insulin\tDB00047\n1\tDB00091\tCyclosporine\tDBMET00359\tCyclosporine M-17 (AM-1)\tDB00091\n1\tDB00091\tCyclosporine\tDBMET02217\tCyclosporine M-1 (AM-9)\tDB00091\n1\tDB00091\tCyclosporine\tDBMET02955\tCyclosporine AM-4N\tDB00091\n*/\n\n\nCREATE TABLE drugbank_drug_reactions_enzymes (\n\tdrugbank_id TEXT, \n\tname TEXT, \n\tuniprot_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_reactions_enzymes table:\ndrugbank_id\tname\tuniprot_id\nBE0002638\tCytochrome P450 3A4\tP08684\nBE0002362\tCytochrome P450 3A5\tP20815\nBE0002638\tCytochrome P450 3A4\tP08684\nBE0002362\tCytochrome P450 3A5\tP20815\nBE0002638\tCytochrome P450 3A4\tP08684\n*/\n\n\nCREATE TABLE drugbank_drug_salts (\n\tdrugbank_id TEXT, \n\tname TEXT, \n\tunii TEXT, \n\tcas_number TEXT, \n\tinchikey TEXT, \n\taverage_mass REAL, \n\tmonoisotopic_mass REAL, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_salts table:\ndrugbank_id\tname\tunii\tcas_number\tinchikey\taverage_mass\tmonoisotopic_mass\tparent_key\nDBSALT000105\tLeuprolide acetate\t37JNS02E7V\t74381-53-6\tYFDMUNOZURYOCP-XNHQSDQCSA-N\t1269.473\t1268.666591578\tDB00007\nDBSALT001439\tSermorelin acetate\t00IBG87IQW\t114466-38-5\tNone\tNone\tNone\tDB00010\nDBSALT000093\tGoserelin acetate\t6YUU2PV0U8\t145781-92-6\tIKDXDQDKCZPQSZ-JHYYTBFNSA-N\t1329.4624\t1328.662568858\tDB00014\nDBSALT001733\tInsulin human zinc suspension\tNone\tNone\tNone\tNone\tNone\tDB00030\nDBSALT001734\tNPH insulin\tNone\t53027-39-7\tNone\tNone\tNone\tDB00030\n*/\n\n\nCREATE TABLE drugbank_drug_sequences (\n\tsequence TEXT, \n\tformat TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_sequences table:\nsequence\tformat\tparent_key\n>DB00001 sequence\nLVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\nEEYLQ\tFASTA\tDB00001\n>Cetuximab heavy chain\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\nTPFTSRLSINKDNSKS\tFASTA\tDB00002\n>Cetuximab light chain\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\nRFSGSGSGTDFTLSIN\tFASTA\tDB00002\n>Dornase alfa sequence\nLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP\nDTYHYVVSEPLGRNSY\tFASTA\tDB00003\n>DB00004 sequence\nMGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK\nYDAAGYSVDNENPLSGKAGGV\tFASTA\tDB00004\n*/\n\n\nCREATE TABLE drugbank_drug_snp_effects (\n\tprotein_name TEXT, \n\tgene_symbol TEXT, \n\tuniprot_id TEXT, \n\trs_id TEXT, \n\tallele TEXT, \n\tdefining_change TEXT, \n\tdescription TEXT, \n\tpubmed_id REAL, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_snp_effects table:\nprotein_name\tgene_symbol\tuniprot_id\trs_id\tallele\tdefining_change\tdescription\tpubmed_id\tparent_key\nLow affinity immunoglobulin gamma Fc region receptor II-a\tFCGR2A\tP12318\trs1801274\tNone\tH allelle\tPatients with this genotype may have increased progression-free survival time when using cetuximab t\t17704420.0\tDB00002\nLow affinity immunoglobulin gamma Fc region receptor III-A\tFCGR3A\tP08637\trs396991\tNone\tG > T\tPatients with this genotype have increased progression-free survival time when using cetuximab to tr\t17704420.0\tDB00002\nInterferon lambda-3\tIFNL3\tQ8IZI9\trs12979860\tNone\tC > T\tPatients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic resp\t24096968.0\tDB00008\nInterferon lambda-3\tIFNL3\tQ8IZI9\trs12979860\tNone\tC > T\tPatients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic resp\t24096968.0\tDB00022\nLow affinity immunoglobulin gamma Fc region receptor III-A\tFCGR3A\tP08637\trs1801274\tNone\tCC Allele (homozygous)\tPatients with this genotype have increased ACR20 response when using infliximab to treat rheumatoid \t18930989.0\tDB00065\n*/\n\n\nCREATE TABLE drugbank_drug_syn (\n\tsynonym TEXT, \n\tlanguage TEXT, \n\tcoder TEXT, \n\tdrugbank_id TEXT\n)\n\n/*\n5 rows from drugbank_drug_syn table:\nsynonym\tlanguage\tcoder\tdrugbank_id\nHirudin variant-1\tenglish\tNone\tDB00001\nLepirudin recombinant\tenglish\tNone\tDB00001\nCetuximab\tenglish/spanish/german\tinn/usan\tDB00002\nCétuximab\tfrench\tinn\tDB00002\nCetuximabum\tlatin\tinn\tDB00002\n*/\n\n\nCREATE TABLE drugbank_drug_targ_articles (\n\tref_id TEXT, \n\tpubmed_id INTEGER, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_targ_articles table:\nref_id\tpubmed_id\tcitation\tparent_key\nA1703\t10505536\tTurpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.\tBE0000048\nA1705\t10912644\tWarkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 J\tBE0000048\nA1707\t11055889\tEriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37\tBE0000048\nA1709\t11467439\tFabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocyto\tBE0000048\nA1711\t11807012\tSzaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrop\tBE0000048\n*/\n\n\nCREATE TABLE drugbank_drug_targ_attachments (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_targ_attachments table:\nref_id\ttitle\turl\tparent_key\nF2122\tRituxan FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/122/original/Rituxan_FDA_l\tBE0000066\nF714\tEMA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/714/original/nivestim_EMA.\tBE0000793\nF719\tTBO filgrastim\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/719/original/TBO_filgrasti\tBE0000793\nF3151\tValsartan HCT monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/151/original/Valsartan_HCT\tBE0000062\nF3202\tProtonix delayed release and oral suspension FDA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/202/original/Protonix_Dela\tBE0000349\n*/\n\n\nCREATE TABLE drugbank_drug_targ_links (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_targ_links table:\nref_id\ttitle\turl\tparent_key\nL4237\tEnbrel (Etanercept) FDA Label\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf\tBE0001087\nL10310\tFDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203696s001lbl.pdf\tBE0000203\nL13781\tFDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042,019732s044lbl.pdf\tBE0000203\nL13784\tFDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020263s046lbl.pdf\tBE0000203\nL13787\tFDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213150s000lbl.pdf\tBE0000203\n*/\n\n\nCREATE TABLE drugbank_drug_targ_textbooks (\n\tref_id TEXT, \n\tisbn TEXT, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_targ_textbooks table:\nref_id\tisbn\tcitation\tparent_key\nT776\t978-1-4939-1405-0\tDenise Rook, Johannes B. van Goudoever (2014). Oxidative Stress and Glutathione Synthesis Rates in E\tBE0000166\nT779\t978-3-030-05314-7\tPeter Weber, Marc Birringer, Jeffrey B. Blumberg, Manfred Eggersdorfer, Jan Frank (2019). Vitamin E \tBE0000076\nT274\t1-57340-221-4\tFrishman W., Cheng-Lai A. and Nawarskas J. (2005). Current cardiovascular drugs (4th ed.). Current m\tBE0000574\nT11\t978-0321556660\tStanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-C\tBE0000062\nT403\t978-1-60413-204-5\tMay S. (2009). Weight-Loss Drugs. Chelsea House Publishers.\tBE0003476\n*/\n\n\nCREATE TABLE drugbank_drug_trans_articles (\n\tref_id TEXT, \n\tpubmed_id INTEGER, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_trans_articles table:\nref_id\tpubmed_id\tcitation\tparent_key\nA15836\t14985103\tNagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr:\tBE0001032\nA15854\t8621716\tBorgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosen\tBE0001032\nA191203\t11707575\tKondratov RV, Komarov PG, Becker Y, Ewenson A, Gudkov AV: Small molecules that dramatically alter mu\tBE0001032\nA15802\t10692506\tMadon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localiz\tBE0001069\nA15910\t8842452\tFricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral a\tBE0001032\n*/\n\n\nCREATE TABLE drugbank_drug_trans_attachments (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_trans_attachments table:\nref_id\ttitle\turl\tparent_key\nF3133\tValsartan Canadian Monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/133/original/Valsartan_HCT\tBE0001004\nF3139\tValsartan HCT Canadian Monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/139/original/Valsartan_HCT\tBE0001069\nF3070\tIn Vitro and In Vivo Evidence of the Importance of Organic Anion Transporters (OATs) in Drug Therapy\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/070/original/e07ffe42a4c1a\tBE0001066\nF3076\tA ROLE OF P-GLYCOPROTEIN IN MODULATION OF ANTIBIOTIC PHARMACOKINETICS\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/076/original/Haritova.pdf?\tBE0002369\nF3103\tInteraction of Cytochrome P450 3A Inhibitors with P-Glycoprotein\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/103/original/4f94dab398541\tBE0001032\n*/\n\n\nCREATE TABLE drugbank_drug_trans_links (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_trans_links table:\nref_id\ttitle\turl\tparent_key\nL3002\tCyclosporine Product Label\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050573s039,050574s047,050625s053lbl.pdf\tBE0001032\nL2953\tFDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers\thttps://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/u\tBE0001032\nL2953\tFDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers\thttps://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/u\tBE0003643\nL11097\tNovartis Monograph: Apo-Cyclosporine\thttps://pdf.hres.ca/dpd_pm/00014004.PDF\tBE0001066\nL2953\tFDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers\thttps://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/u\tBE0001004\n*/\n\n\nCREATE TABLE drugbank_drug_trans_textbooks (\n\tref_id TEXT, \n\tisbn TEXT, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drug_trans_textbooks table:\nref_id\tisbn\tcitation\tparent_key\nT244\tNone\tColeman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.\tBE0001004\nT338\t978-1-84973-828-6\tWilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society\tBE0000703\nT338\t978-1-84973-828-6\tWilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society\tBE0000703\nT338\t978-1-84973-828-6\tWilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society\tBE0000703\nT768\tNone\tAlexander Alex, C. John Harris, Dennis A. Smith (2016). Attrition in the Pharmaceutical industry: re\tBE0004782\n*/\n\n\nCREATE TABLE drugbank_drugs_articles (\n\tref_id TEXT, \n\tpubmed_id REAL, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drugs_articles table:\nref_id\tpubmed_id\tcitation\tparent_key\nA1\t16244762.0\tSmythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. C\tDB00001\nA2\t16690967.0\tTardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, R\tDB00001\nA3\t16241940.0\tLubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytop\tDB00001\nA4\t10480573.0\tHosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin\tDB00002\nA5\t10601294.0\tWakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differen\tDB00002\n*/\n\n\nCREATE TABLE drugbank_drugs_attachments (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drugs_attachments table:\nref_id\ttitle\turl\tparent_key\nF85\tEMA Summary of Product Characteristics: RETACRIT (epoetin alfa-epox) injection, for intravenous or s\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/085/original/WC500054377.p\tDB00016\nF86\tEpoetin Alfa (Epogen®) Product Monograph\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/086/original/EpoetinAlfaMo\tDB00016\nF1946\tXolair EMA label\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/946/original/Xolair_EMA_la\tDB00043\nF2118\tHUMIRA FDA LABEL\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/118/original/Humira_FDA_la\tDB00051\nF229\tAlbuminex package insert\t//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/229/original/Package_Inser\tDB00062\n*/\n\n\nCREATE TABLE drugbank_drugs_links (\n\tref_id TEXT, \n\ttitle TEXT, \n\turl TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drugs_links table:\nref_id\ttitle\turl\tparent_key\nL48\tGoogle books\thttp://books.google.com/books?id=iadLoXoQkWEC&pg=PA440\tDB00001\nL10310\tFDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203696s001lbl.pdf\tDB00007\nL13781\tFDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042,019732s044lbl.pdf\tDB00007\nL13784\tFDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020263s046lbl.pdf\tDB00007\nL13787\tFDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension\thttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213150s000lbl.pdf\tDB00007\n*/\n\n\nCREATE TABLE drugbank_drugs_textbooks (\n\tref_id TEXT, \n\tisbn TEXT, \n\tcitation TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_drugs_textbooks table:\nref_id\tisbn\tcitation\tparent_key\nT28\t978-0-7020-3471-8\t32. (2012). In Rang and Dale\'s Pharmacology  (7th ed., pp. 399-400). Edinburgh: Elsevier/Churchill L\tDB00035\nT180\t978-1-4160-0208-6\tShorr R., Hoth A. and Rawls N. (2007). Drugs for the Geriatric Patient. Elsevier.\tDB00085\nT454\tNone\tAmidon, Gordon L., Sadée, Wolfgang (2002). Vitamin B12 Transporters (12th ed.). Springer, Boston MA.\tDB00115\nT577\t978-012-374118-9\tCoulston A. and Boushey C. (2008). Nutrition in the Prevention and Treatment of Disease (2nd ed.). A\tDB00153\nT580\t978-0-8493-9771-4\tEitenmiller R., Ye L. and Landen W. (2008). Vitamin analysis for the health and food sciences (2nd e\tDB00153\n*/\n\n\nCREATE TABLE drugbank_enzymes (\n\tid TEXT, \n\tname TEXT, \n\torganism TEXT, \n\tknown_action TEXT, \n\tposition REAL, \n\tparent_key TEXT, \n\tinhibition_strength TEXT, \n\tinduction_strength TEXT\n)\n\n/*\n5 rows from drugbank_enzymes table:\nid\tname\torganism\tknown_action\tposition\tparent_key\tinhibition_strength\tinduction_strength\nBE0001075\tMyeloperoxidase\tHumans\tunknown\t1.0\tDB00006\tunknown\tNone\nBE0002433\tCytochrome P450 1A2\tHumans\tunknown\t1.0\tDB00008\tunknown\tNone\nBE0002433\tCytochrome P450 1A2\tHumans\tunknown\t3.0\tDB00011\tunknown\tNone\nBE0001198\tMacrophage metalloelastase\tHumans\tunknown\t9.0\tDB00013\tNone\tNone\nBE0002433\tCytochrome P450 1A2\tHumans\tunknown\t1.0\tDB00018\tunknown\tNone\n*/\n\n\nCREATE TABLE drugbank_enzymes_actions (\n\taction TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_actions table:\naction\tparent_id\ninhibitor\tBE0001075\ninhibitor\tBE0002433\nsubstrate\tBE0001198\nsubstrate\tBE0000394\ninhibitor\tBE0002363\n*/\n\n\nCREATE TABLE drugbank_enzymes_polypeptides (\n\tid TEXT, \n\tsource TEXT, \n\tname TEXT, \n\tgeneral_function TEXT, \n\tspecific_function TEXT, \n\tgene_name TEXT, \n\tlocus TEXT, \n\tcellular_location TEXT, \n\ttransmembrane_regions TEXT, \n\tsignal_regions TEXT, \n\ttheoretical_pi REAL, \n\tmolecular_weight REAL, \n\tchromosome_location REAL, \n\torganism TEXT, \n\torganism_ncbi_taxonomy_id REAL, \n\tamino_acid_sequence TEXT, \n\tamino_acid_format TEXT, \n\tgene_sequence TEXT, \n\tgene_format TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_polypeptides table:\nid\tsource\tname\tgeneral_function\tspecific_function\tgene_name\tlocus\tcellular_location\ttransmembrane_regions\tsignal_regions\ttheoretical_pi\tmolecular_weight\tchromosome_location\torganism\torganism_ncbi_taxonomy_id\tamino_acid_sequence\tamino_acid_format\tgene_sequence\tgene_format\tparent_id\nP05164\tSwiss-Prot\tMyeloperoxidase\tPeroxidase activity\tPart of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal \tMPO\t17q23.1\tLysosome\tNone\t1-48\t9.14\t83867.71\tNone\tHumans\t9606.0\t>lcl|BSEQ0002139|Myeloperoxidase\nMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS\nLVLSSM\tFASTA\t>lcl|BSEQ0016304|Myeloperoxidase (MPO)\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\n\tFASTA\tBE0001075\nP05177\tSwiss-Prot\tCytochrome P450 1A2\tOxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxyge\tCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is in\tCYP1A2\t15q24\tEndoplasmic reticulum membrane\tNone\tNone\t9.43\t58293.76\tNone\tHumans\t9606.0\t>lcl|BSEQ0004778|Cytochrome P450 1A2\nMALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN\nPH\tFASTA\t>lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)\nATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCT\tFASTA\tBE0002433\nP39900\tSwiss-Prot\tMacrophage metalloelastase\tZinc ion binding\tMay be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept la\tMMP12\t11q22.3\tSecreted\tNone\t1-16\t8.98\t54001.175\tNone\tHumans\t9606.0\t>lcl|BSEQ0010834|Macrophage metalloelastase\nMKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYS\tFASTA\t>lcl|BSEQ0010835|Macrophage metalloelastase (MMP12)\nATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCACTGCTTCTGGAGCT\tFASTA\tBE0001198\nP08246\tSwiss-Prot\tNeutrophil elastase\tSerine-type endopeptidase activity\tModifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent n\tELANE\t19p13.3\tCytoplasmic\tNone\t1-27\t9.41\t28517.81\tNone\tHumans\t9606.0\t>lcl|BSEQ0000785|Neutrophil elastase\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAP\tFASTA\t>lcl|BSEQ0010273|Neutrophil elastase (ELANE)\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCT\tFASTA\tBE0000394\nP10635\tSwiss-Prot\tCytochrome P450 2D6\tSteroid hydroxylase activity\tResponsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is inv\tCYP2D6\t22q13.1\tEndoplasmic reticulum membrane\tNone\tNone\t7.26\t55768.94\tNone\tHumans\t9606.0\t>lcl|BSEQ0004641|Cytochrome P450 2D6\nMGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ\nLR\tFASTA\t>lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)\nATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTC\tFASTA\tBE0002363\n*/\n\n\nCREATE TABLE drugbank_enzymes_polypeptides_ext_id (\n\tresource TEXT, \n\tidentifier TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_polypeptides_ext_id table:\nresource\tidentifier\tparent_key\nHUGO Gene Nomenclature Committee (HGNC)\tHGNC:7218\tBE0001075\nGenAtlas\tMPO\tBE0001075\nGenBank Gene Database\tJ02694\tBE0001075\nGenBank Protein Database\t189040\tBE0001075\nGuide to Pharmacology\t2789\tBE0001075\n*/\n\n\nCREATE TABLE drugbank_enzymes_polypeptides_go (\n\tcategory TEXT, \n\tdescription TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_polypeptides_go table:\ncategory\tdescription\tparent_key\ncomponent\tazurophil granule\tBE0001075\ncomponent\textracellular exosome\tBE0001075\ncomponent\textracellular space\tBE0001075\ncomponent\tlysosome\tBE0001075\ncomponent\tmitochondrion\tBE0001075\n*/\n\n\nCREATE TABLE drugbank_enzymes_polypeptides_pfams (\n\tidentifier TEXT, \n\tname TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_polypeptides_pfams table:\nidentifier\tname\tparent_key\nPF03098\tAn_peroxidase\tBE0001075\nPF00067\tp450\tBE0002433\nPF00045\tHemopexin\tBE0001198\nPF00413\tPeptidase_M10\tBE0001198\nPF01471\tPG_binding_1\tBE0001198\n*/\n\n\nCREATE TABLE drugbank_enzymes_polypeptides_syn (\n\ttext TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_enzymes_polypeptides_syn table:\ntext\tparent_key\n1.11.2.2\tBE0001075\nMPO\tBE0001075\n1.14.14.1\tBE0002433\nCholesterol 25-hydroxylase\tBE0002433\nCYPIA2\tBE0002433\n*/\n\n\nCREATE TABLE drugbank_query_ddi_table (\n\tdrug1 TEXT, \n\tdrug2 TEXT, \n\tinteraction TEXT\n)\n\n/*\n5 rows from drugbank_query_ddi_table table:\ndrug1\tdrug2\tinteraction\nApixaban\tLepirudin\tApixaban may increase the anticoagulant activities of Lepirudin.\nNorgestimate\tLepirudin\tNorgestimate may decrease the anticoagulant activities of Lepirudin.\nPhenindione\tLepirudin\tThe risk or severity of bleeding can be increased \nCefradine\tLepirudin\tThe therapeutic efficacy of Lepirudin can be decreased \nRavulizumab\tCetuximab\tThe risk or severity of adverse effects can be increased \n*/\n\n\nCREATE TABLE drugbank_snp_adverse_reactions (\n\tprotein_name TEXT, \n\tgene_symbol TEXT, \n\tuniprot_id TEXT, \n\trs_id TEXT, \n\tallele TEXT, \n\tadverse_reaction TEXT, \n\tdescription TEXT, \n\tpubmed_id REAL, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_snp_adverse_reactions table:\nprotein_name\tgene_symbol\tuniprot_id\trs_id\tallele\tadverse_reaction\tdescription\tpubmed_id\tparent_key\nReceptor tyrosine-protein kinase erbB-2\tERBB2\tP04626\trs1136201\tNone\tG Allele, heterozygote\tPatients with this genotype have increased risk of cardiotoxicity with trastuzumab.\t17693647.0\tDB00072\nCytochrome P450 1A2\tCYP1A2\tP05177\trs762551\tNone\tC allele\tPatients with this genotype have increased risk of a non-fatal myocardial infarction with caffeine\t16522833.0\tDB00201\nGlutamate receptor ionotropic, kainate 2\tGRIK2\tQ13002\trs2518224\tNone\tC Allele, homozygote\tPatients with this genotype have increased frequency of suicidal ideation with citalopram\t17898344.0\tDB00215\nGlutamate receptor 3\tGRIA3\tP42263\trs4825476\tNone\tG allele\tPatients with this genotype have increased frequency of suicidal ideation with citalopram\t17898344.0\tDB00215\nCyclic AMP-responsive element-binding protein 1\tCREB1\tP16220\trs4675690\tNone\tT allele, homozygous\tMale patients with this genotype have an increased risk of (condition: suicide) with (drug: citalopr\t17548750.0\tDB00215\n*/\n\n\nCREATE TABLE drugbank_targets (\n\tid TEXT, \n\tname TEXT, \n\torganism TEXT, \n\tknown_action TEXT, \n\tposition REAL, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_targets table:\nid\tname\torganism\tknown_action\tposition\tparent_key\nBE0000048\tProthrombin\tHumans\tyes\tNone\tDB00001\nBE0000767\tEpidermal growth factor receptor\tHumans\tyes\t1.0\tDB00002\nBE0000901\tLow affinity immunoglobulin gamma Fc region receptor III-B\tHumans\tunknown\t2.0\tDB00002\nBE0002094\tComplement C1q subcomponent subunit A\tHumans\tunknown\t3.0\tDB00002\nBE0002095\tComplement C1q subcomponent subunit B\tHumans\tunknown\t4.0\tDB00002\n*/\n\n\nCREATE TABLE drugbank_targets_actions (\n\taction TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_targets_actions table:\naction\tparent_id\ninhibitor\tBE0000048\nantagonist\tBE0000767\nbinder\tBE0000658\nagonist\tBE0000651\nantibody\tBE0000704\n*/\n\n\nCREATE TABLE drugbank_targets_polypeptides (\n\tid TEXT, \n\tsource TEXT, \n\tname TEXT, \n\tgeneral_function TEXT, \n\tspecific_function TEXT, \n\tgene_name TEXT, \n\tlocus TEXT, \n\tcellular_location TEXT, \n\ttransmembrane_regions TEXT, \n\tsignal_regions TEXT, \n\ttheoretical_pi REAL, \n\tmolecular_weight REAL, \n\tchromosome_location REAL, \n\torganism TEXT, \n\torganism_ncbi_taxonomy_id REAL, \n\tamino_acid_sequence TEXT, \n\tamino_acid_format TEXT, \n\tgene_sequence TEXT, \n\tgene_format TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_targets_polypeptides table:\nid\tsource\tname\tgeneral_function\tspecific_function\tgene_name\tlocus\tcellular_location\ttransmembrane_regions\tsignal_regions\ttheoretical_pi\tmolecular_weight\tchromosome_location\torganism\torganism_ncbi_taxonomy_id\tamino_acid_sequence\tamino_acid_format\tgene_sequence\tgene_format\tparent_id\nP00734\tSwiss-Prot\tProthrombin\tThrombospondin receptor activity\tThrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors\tF2\t11p11-q12\tSecreted\tNone\t1-24\t5.7\t70036.295\tNone\tHumans\t9606.0\t>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEA\tFASTA\t>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGT\tFASTA\tBE0000048\nP00533\tSwiss-Prot\tEpidermal growth factor receptor\tUbiquitin protein ligase binding\tReceptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades\tEGFR\t7p12\tCell membrane\t646-668\t1-24\t6.67\t134276.185\tNone\tHumans\t9606.0\t>lcl|BSEQ0001530|Epidermal growth factor receptor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLS\tFASTA\t>lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGC\tFASTA\tBE0000767\nO75015\tSwiss-Prot\tLow affinity immunoglobulin gamma Fc region receptor III-B\tNone\tReceptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggre\tFCGR3B\t1q23\tCell membrane\tNone\t1-16\t6.71\t26215.64\tNone\tHumans\t9606.0\t>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLP\tFASTA\t>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTC\tFASTA\tBE0000901\nP02745\tSwiss-Prot\tComplement C1q subcomponent subunit A\tNone\tC1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complem\tC1QA\t1p36.12\tSecreted\tNone\t1-22\t9.45\t26016.47\tNone\tHumans\t9606.0\t>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRP\tFASTA\t>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCT\tFASTA\tBE0002094\nP02746\tSwiss-Prot\tComplement C1q subcomponent subunit B\tNone\tC1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complem\tC1QB\t1p36.12\tSecreted\tNone\t1-27\t8.87\t26721.62\tNone\tHumans\t9606.0\t>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPG\tFASTA\t>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACT\tFASTA\tBE0002095\n*/\n\n\nCREATE TABLE drugbank_targets_polypeptides_ext_id (\n\tresource TEXT, \n\tidentifier TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_targets_polypeptides_ext_id table:\nresource\tidentifier\tparent_key\nHUGO Gene Nomenclature Committee (HGNC)\tHGNC:3535\tBE0000048\nGenAtlas\tF2\tBE0000048\nGenBank Gene Database\tM17262\tBE0000048\nGenBank Protein Database\t339641\tBE0000048\nGuide to Pharmacology\t2362\tBE0000048\n*/\n\n\nCREATE TABLE drugbank_targets_polypeptides_go (\n\tcategory TEXT, \n\tdescription TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_targets_polypeptides_go table:\ncategory\tdescription\tparent_key\ncomponent\tblood microparticle\tBE0000048\ncomponent\tcytosol\tBE0000048\ncomponent\tendoplasmic reticulum lumen\tBE0000048\ncomponent\textracellular exosome\tBE0000048\ncomponent\textracellular matrix\tBE0000048\n*/\n\n\nCREATE TABLE drugbank_targets_polypeptides_pfams (\n\tidentifier TEXT, \n\tname TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_targets_polypeptides_pfams table:\nidentifier\tname\tparent_key\nPF00594\tGla\tBE0000048\nPF00051\tKringle\tBE0000048\nPF00089\tTrypsin\tBE0000048\nPF09396\tThrombin_light\tBE0000048\nPF07714\tPkinase_Tyr\tBE0000767\n*/\n\n\nCREATE TABLE drugbank_targets_polypeptides_syn (\n\ttext TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_targets_polypeptides_syn table:\ntext\tparent_key\n3.4.21.5\tBE0000048\nCoagulation factor II\tBE0000048\n2.7.10.1\tBE0000767\nERBB\tBE0000767\nERBB1\tBE0000767\n*/\n\n\nCREATE TABLE drugbank_transporters (\n\tid TEXT, \n\tname TEXT, \n\torganism TEXT, \n\tknown_action TEXT, \n\tposition INTEGER, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_transporters table:\nid\tname\torganism\tknown_action\tposition\tparent_key\nBE0001032\tP-glycoprotein 1\tHumans\tunknown\t1\tDB00027\nBE0001069\tCanalicular multispecific organic anion transporter 1\tHumans\tunknown\t4\tDB00067\nBE0001032\tP-glycoprotein 1\tHumans\tunknown\t4\tDB00091\nBE0000703\tBile salt export pump\tHumans\tunknown\t5\tDB00091\nBE0003643\tIleal sodium/bile acid cotransporter\tHumans\tunknown\t6\tDB00091\n*/\n\n\nCREATE TABLE drugbank_transporters_actions (\n\taction TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_transporters_actions table:\naction\tparent_id\nsubstrate\tBE0001032\ninhibitor\tBE0001032\nsubstrate\tBE0001069\nsubstrate\tBE0000703\ninhibitor\tBE0000703\n*/\n\n\nCREATE TABLE drugbank_transporters_polypeptides (\n\tid TEXT, \n\tsource TEXT, \n\tname TEXT, \n\tgeneral_function TEXT, \n\tspecific_function TEXT, \n\tgene_name TEXT, \n\tlocus TEXT, \n\tcellular_location TEXT, \n\ttransmembrane_regions TEXT, \n\tsignal_regions TEXT, \n\ttheoretical_pi REAL, \n\tmolecular_weight REAL, \n\tchromosome_location REAL, \n\torganism TEXT, \n\torganism_ncbi_taxonomy_id INTEGER, \n\tamino_acid_sequence TEXT, \n\tamino_acid_format TEXT, \n\tgene_sequence TEXT, \n\tgene_format TEXT, \n\tparent_id TEXT\n)\n\n/*\n5 rows from drugbank_transporters_polypeptides table:\nid\tsource\tname\tgeneral_function\tspecific_function\tgene_name\tlocus\tcellular_location\ttransmembrane_regions\tsignal_regions\ttheoretical_pi\tmolecular_weight\tchromosome_location\torganism\torganism_ncbi_taxonomy_id\tamino_acid_sequence\tamino_acid_format\tgene_sequence\tgene_format\tparent_id\nP08183\tSwiss-Prot\tMultidrug resistance protein 1\tXenobiotic-transporting atpase activity\tEnergy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cell\tABCB1\t7q21.1\tCell membrane\t45-67\n117-137\n187-208\n216-236\n293-316\n331-352\n712-732\n757-777\n833-853\n855-874\n935-957\n974-995\tNone\t9.44\t141477.255\tNone\tHumans\t9606\t>lcl|BSEQ0037114|Multidrug resistance protein 1\nMDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMV\tFASTA\t>lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)\nATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAA\tFASTA\tBE0001032\nQ92887\tSwiss-Prot\tCanalicular multispecific organic anion transporter 1\tOrganic anion transmembrane transporter activity\tMediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin tr\tABCC2\t10q24\tApical cell membrane\t28-48\n69-89\n94-114\n127-147\n166-186\n314-334\n361-381\n438-458\n462-482\n545-565\n588-608\n972-992\n1034-1054\tNone\t8.46\t174205.64\tNone\tHumans\t9606\t>lcl|BSEQ0010748|Canalicular multispecific organic anion transporter 1\nMLEKFCNSTFWNSSFLDSPEADLPLCFEQ\tFASTA\t>lcl|BSEQ0010749|Canalicular multispecific organic anion transporter 1 (ABCC2)\nATGCTGGAGAAGTTCTGCAAC\tFASTA\tBE0001069\nO95342\tSwiss-Prot\tBile salt export pump\tTransporter activity\tInvolved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.\tABCB11\t2q24\tMembrane\t63-83\n148-168\n216-236\n241-261\n320-340\n354-374\n756-776\n795-815\n870-890\n891-911\n980-1000\n1012-1032\tNone\t6.52\t146405.83\tNone\tHumans\t9606\t>lcl|BSEQ0010492|Bile salt export pump\nMSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW\n\tFASTA\t>lcl|BSEQ0010493|Bile salt export pump (ABCB11)\nATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATG\tFASTA\tBE0000703\nQ12908\tSwiss-Prot\tIleal sodium/bile acid cotransporter\tBile acid:sodium symporter activity\tPlays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small\tSLC10A2\t13q33\tMembrane\t29-49\n83-103\n127-147\n158-178\n196-216\n225-245\n285-305\tNone\t7.13\t37713.405\tNone\tHumans\t9606\t>lcl|BSEQ0012533|Ileal sodium/bile acid cotransporter\nMNDPNSCVDNATVCSGASCVVPESNFNNILSVVLSTVLTILLALVM\tFASTA\t>lcl|BSEQ0012534|Ileal sodium/bile acid cotransporter (SLC10A2)\nATGAATGATCCGAACAGCTGTGTGGACAATGCAACA\tFASTA\tBE0003643\nQ14973\tSwiss-Prot\tSodium/bile acid cotransporter\tVirus receptor activity\tThe hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports vario\tSLC10A1\t14q24.1\tMembrane\t25-45\n60-80\n91-111\n120-140\n156-176\n191-211\n220-240\n283-303\tNone\t8.94\t38118.64\tNone\tHumans\t9606\t>lcl|BSEQ0017172|Sodium/bile acid cotransporter\nMEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIK\tFASTA\t>lcl|BSEQ0017173|Sodium/bile acid cotransporter (SLC10A1)\nATGGAGGCCCACAACGCGTCTGCCCCATTCAACTTCACCCTG\tFASTA\tBE0003644\n*/\n\n\nCREATE TABLE drugbank_transporters_polypeptides_ext_id (\n\tresource TEXT, \n\tidentifier TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_transporters_polypeptides_ext_id table:\nresource\tidentifier\tparent_key\nHUGO Gene Nomenclature Committee (HGNC)\tHGNC:40\tBE0001032\nGenAtlas\tABCB1\tBE0001032\nGenBank Gene Database\tM14758\tBE0001032\nGenBank Protein Database\t307180\tBE0001032\nUniProtKB\tP08183\tBE0001032\n*/\n\n\nCREATE TABLE drugbank_transporters_polypeptides_go (\n\tcategory TEXT, \n\tdescription TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_transporters_polypeptides_go table:\ncategory\tdescription\tparent_key\ncomponent\tcell surface\tBE0001032\ncomponent\textracellular exosome\tBE0001032\ncomponent\tintegral component of membrane\tBE0001032\ncomponent\tmembrane\tBE0001032\ncomponent\tplasma membrane\tBE0001032\n*/\n\n\nCREATE TABLE drugbank_transporters_polypeptides_pfams (\n\tidentifier TEXT, \n\tname TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_transporters_polypeptides_pfams table:\nidentifier\tname\tparent_key\nPF00005\tABC_tran\tBE0001032\nPF00664\tABC_membrane\tBE0001032\nPF00005\tABC_tran\tBE0001069\nPF00664\tABC_membrane\tBE0001069\nPF00005\tABC_tran\tBE0000703\n*/\n\n\nCREATE TABLE drugbank_transporters_polypeptides_syn (\n\ttext TEXT, \n\tparent_key TEXT\n)\n\n/*\n5 rows from drugbank_transporters_polypeptides_syn table:\ntext\tparent_key\n3.6.3.44\tBE0001032\nATP-binding cassette sub-family B member 1\tBE0001032\nMDR1\tBE0001032\nP-glycoprotein 1\tBE0001032\nPGY1\tBE0001032\n*/', 'role': 'user'}], 'model': 'gpt-4o', 'parallel_tool_calls': False, 'stream': False, 'temperature': 0.0, 'tool_choice': {'type': 'function', 'function': {'name': 'ExecuteCode'}}, 'tools': [{'type': 'function', 'function': {'name': 'ExecuteCode', 'description': '', 'parameters': {'type': 'object', 'properties': {'reasoning': {'description': 'The reasoning behind the SQL expression, including how context is included, if applicable.', 'type': 'string'}, 'SQL': {'description': 'The SQL Code that can be runnable on the corresponding database ', 'type': 'string'}}, 'required': ['reasoning', 'SQL']}}}]}}
2025-04-07 10:23:45,651 - openai._base_client - DEBUG - Sending HTTP Request: POST https://api.openai.com/v1/chat/completions
2025-04-07 10:23:45,651 - httpcore.connection - DEBUG - connect_tcp.started host='api.openai.com' port=443 local_address=None timeout=None socket_options=None
2025-04-07 10:23:45,663 - httpcore.connection - DEBUG - connect_tcp.complete return_value=<httpcore._backends.sync.SyncStream object at 0x16f9e6b60>
2025-04-07 10:23:45,663 - httpcore.connection - DEBUG - start_tls.started ssl_context=<ssl.SSLContext object at 0x2a343f540> server_hostname='api.openai.com' timeout=None
2025-04-07 10:23:45,677 - httpcore.connection - DEBUG - start_tls.complete return_value=<httpcore._backends.sync.SyncStream object at 0x16f9e6bf0>
2025-04-07 10:23:45,677 - httpcore.http11 - DEBUG - send_request_headers.started request=<Request [b'POST']>
2025-04-07 10:23:45,678 - httpcore.http11 - DEBUG - send_request_headers.complete
2025-04-07 10:23:45,678 - httpcore.http11 - DEBUG - send_request_body.started request=<Request [b'POST']>
2025-04-07 10:23:45,678 - httpcore.http11 - DEBUG - send_request_body.complete
2025-04-07 10:23:45,678 - httpcore.http11 - DEBUG - receive_response_headers.started request=<Request [b'POST']>
2025-04-07 10:23:46,379 - urllib3.connectionpool - DEBUG - https://api.smith.langchain.com:443 "POST /runs/multipart HTTP/1.1" 202 34
2025-04-07 10:23:55,160 - httpcore.http11 - DEBUG - receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Date', b'Mon, 07 Apr 2025 14:23:55 GMT'), (b'Content-Type', b'application/json'), (b'Transfer-Encoding', b'chunked'), (b'Connection', b'keep-alive'), (b'access-control-expose-headers', b'X-Request-ID'), (b'openai-organization', b'user-c4kmud4pram6lu62sxpadvux'), (b'openai-processing-ms', b'9352'), (b'openai-version', b'2020-10-01'), (b'x-ratelimit-limit-requests', b'5000'), (b'x-ratelimit-limit-tokens', b'800000'), (b'x-ratelimit-remaining-requests', b'4999'), (b'x-ratelimit-remaining-tokens', b'784385'), (b'x-ratelimit-reset-requests', b'12ms'), (b'x-ratelimit-reset-tokens', b'1.171s'), (b'x-request-id', b'req_e0edccd86c2287fadb6ea1ee2394ddcf'), (b'strict-transport-security', b'max-age=31536000; includeSubDomains; preload'), (b'cf-cache-status', b'DYNAMIC'), (b'Set-Cookie', b'__cf_bm=x.hlkAfaGSMzDTPGv8pSDIBGeAA.AT3PPAfOO4VQjrg-1744035835-1.0.1.1-i_a0XZ5JwHzGawENiPcpmbdhz9bYzQuMFRcoDbyCa6Paw7fsbtPGXIVmoHE1psLAUg0Dc7gSgj9SBJmbAecZ2sbPgyk0ZTNHT64nWpzVcAc; path=/; expires=Mon, 07-Apr-25 14:53:55 GMT; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), (b'X-Content-Type-Options', b'nosniff'), (b'Set-Cookie', b'_cfuvid=SiGTITphpkQwDIngFmnguornhshlHOigRmc8oARGR2w-1744035835197-0.0.1.1-604800000; path=/; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), (b'Server', b'cloudflare'), (b'CF-RAY', b'92ca2f46ccfeebc0-YYZ'), (b'Content-Encoding', b'gzip'), (b'alt-svc', b'h3=":443"; ma=86400')])
2025-04-07 10:23:55,162 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2025-04-07 10:23:55,163 - httpcore.http11 - DEBUG - receive_response_body.started request=<Request [b'POST']>
2025-04-07 10:23:55,163 - httpcore.http11 - DEBUG - receive_response_body.complete
2025-04-07 10:23:55,164 - httpcore.http11 - DEBUG - response_closed.started
2025-04-07 10:23:55,164 - httpcore.http11 - DEBUG - response_closed.complete
2025-04-07 10:23:55,164 - openai._base_client - DEBUG - HTTP Response: POST https://api.openai.com/v1/chat/completions "200 OK" Headers([('date', 'Mon, 07 Apr 2025 14:23:55 GMT'), ('content-type', 'application/json'), ('transfer-encoding', 'chunked'), ('connection', 'keep-alive'), ('access-control-expose-headers', 'X-Request-ID'), ('openai-organization', 'user-c4kmud4pram6lu62sxpadvux'), ('openai-processing-ms', '9352'), ('openai-version', '2020-10-01'), ('x-ratelimit-limit-requests', '5000'), ('x-ratelimit-limit-tokens', '800000'), ('x-ratelimit-remaining-requests', '4999'), ('x-ratelimit-remaining-tokens', '784385'), ('x-ratelimit-reset-requests', '12ms'), ('x-ratelimit-reset-tokens', '1.171s'), ('x-request-id', 'req_e0edccd86c2287fadb6ea1ee2394ddcf'), ('strict-transport-security', 'max-age=31536000; includeSubDomains; preload'), ('cf-cache-status', 'DYNAMIC'), ('set-cookie', '__cf_bm=x.hlkAfaGSMzDTPGv8pSDIBGeAA.AT3PPAfOO4VQjrg-1744035835-1.0.1.1-i_a0XZ5JwHzGawENiPcpmbdhz9bYzQuMFRcoDbyCa6Paw7fsbtPGXIVmoHE1psLAUg0Dc7gSgj9SBJmbAecZ2sbPgyk0ZTNHT64nWpzVcAc; path=/; expires=Mon, 07-Apr-25 14:53:55 GMT; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), ('x-content-type-options', 'nosniff'), ('set-cookie', '_cfuvid=SiGTITphpkQwDIngFmnguornhshlHOigRmc8oARGR2w-1744035835197-0.0.1.1-604800000; path=/; domain=.api.openai.com; HttpOnly; Secure; SameSite=None'), ('server', 'cloudflare'), ('cf-ray', '92ca2f46ccfeebc0-YYZ'), ('content-encoding', 'gzip'), ('alt-svc', 'h3=":443"; ma=86400')])
2025-04-07 10:23:55,164 - openai._base_client - DEBUG - request_id: req_e0edccd86c2287fadb6ea1ee2394ddcf
2025-04-07 10:23:55,210 - httpcore.http11 - DEBUG - receive_response_body.complete
2025-04-07 10:23:55,210 - httpcore.http11 - DEBUG - response_closed.started
2025-04-07 10:23:55,210 - httpcore.http11 - DEBUG - response_closed.complete
2025-04-07 10:23:55,219 - openai._base_client - DEBUG - Request options: {'method': 'post', 'url': '/chat/completions', 'files': None, 'json_data': {'messages': [{'content': "Solve a question answering task. Here are some guidelines:\n    - In the Assistant Scratchpad, you will be given results of a plan you have executed to answer the user's question.\n    - Thought needs to reason about the question based on the Observations in 1-2 sentences.\n    - Ignore irrelevant action results.\n    - If the required information is present, give a concise but complete and helpful answer to the user's question.\n    - If you are unable to give a satisfactory finishing answer, replan to get the required information. Respond in the following format:\n    Thought: <reason about the task results and whether you have sufficient information to answer the question>\n    Action: <action to take>\n    - If an error occurs during previous actions, replan and take corrective measures to obtain the required information.\n    - Ensure that you consider errors in all the previous steps, and tries to replan accordingly.\n    - Ensure the final answer is provided in a structured format as JSON as follows:\n        {'Summary': <concise summary of the answer>,\n         'details': <detailed explanation and supporting information>,\n         'source': <source of the information or how it was obtained>,\n         'inference':<your final inference as YES, No, or list of requested information without any extra information which you can take from the `labels` as given below>,\n         'extra explanation':<put here the extra information that you dont provide in inference >,\n         }\n         In the `inferencer` do not provide additinal explanation or description. Put them in `extra explanation`.\n\n       \n    Available actions:\n    (1) Finish(the final answer to return to the user): returns the answer and finishes the task.\n    (2) Replan(the reasoning and other information that will help you plan again. Can be a line of any length): instructs why we must replan\n    ", 'role': 'system'}, {'content': '[HumanMessage(content=\'What is the mechanism of action for Cetuximab and which receptor does it target?\', additional_kwargs={}, response_metadata={}, id=\'2f199225-4621-4caf-a8fa-27a519ef417b\'), FunctionMessage(content="{\'status\': \'success\', \'data\': [{\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Complement C1q subcomponent subunit A\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Complement C1q subcomponent subunit B\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Complement C1q subcomponent subunit C\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Epidermal growth factor receptor\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'High affinity immunoglobulin gamma Fc receptor I\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Low affinity immunoglobulin gamma Fc region receptor II-a\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Low affinity immunoglobulin gamma Fc region receptor III-A\'}, {\'mechanism_of_action\': \'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.\', \'receptor_targeted\': \'Low affinity immunoglobulin gamma Fc region receptor III-B\'}]}", additional_kwargs={\'idx\': 1, \'args\': {\'problem\': \'What is the mechanism of action for Cetuximab and which receptor does it target?\'}}, response_metadata={}, name=\'text2SQL\', id=\'af54733e-c4c9-4d26-8a18-39040c90c0b2\'), FunctionMessage(content=\'join\', additional_kwargs={\'idx\': 2, \'args\': ()}, response_metadata={}, name=\'join\', id=\'cb2dc3d1-9b7d-4e8b-8d79-37ee6e3c8ff9\')]', 'role': 'user'}, {'content': '\n        Using the above previous actions, decide whether to replan or finish. \n        If all the required information is present, you may finish. \n        If you have made many attempts to find the information without success, admit so and respond with whatever information you have gathered so the user can work well with you. \n        ', 'role': 'assistant'}], 'model': 'gpt-4o', 'function_call': {'name': '_OutputFormatter'}, 'functions': [{'name': '_OutputFormatter', 'description': 'Output formatter. Should always be used to format your response to the user.', 'parameters': {'properties': {'output': {'description': 'Decide whether to replan or whether you can return the final response.', 'examples': [{'action': {'response': 'Example response'}, 'thought': 'Example thought process'}], 'properties': {'thought': {'description': 'The chain of thought reasoning for the selected action', 'type': 'string'}, 'action': {'anyOf': [{'description': 'The final response/answer.', 'examples': [{'response': "Example response or {'key': 'value'}"}], 'properties': {'response': {'anyOf': [{'type': 'string'}, {'additionalProperties': True, 'type': 'object'}], 'title': 'Response'}}, 'required': ['response'], 'title': 'FinalResponse', 'type': 'object'}, {'description': 'Model for replanning feedback', 'examples': [{'feedback': 'Analysis of what went wrong and what needs to be fixed'}], 'properties': {'feedback': {'description': 'Analysis of the previous attempts and recommendations on what needs to be fixed.', 'title': 'Feedback', 'type': 'string'}}, 'required': ['feedback'], 'title': 'Replan', 'type': 'object'}]}}, 'required': ['thought', 'action'], 'type': 'object'}}, 'required': ['output'], 'type': 'object'}}], 'stream': False, 'temperature': 0.0}}
2025-04-07 10:23:55,220 - openai._base_client - DEBUG - Sending HTTP Request: POST https://api.openai.com/v1/chat/completions
2025-04-07 10:23:55,220 - httpcore.http11 - DEBUG - send_request_headers.started request=<Request [b'POST']>
2025-04-07 10:23:55,220 - httpcore.http11 - DEBUG - send_request_headers.complete
2025-04-07 10:23:55,220 - httpcore.http11 - DEBUG - send_request_body.started request=<Request [b'POST']>
2025-04-07 10:23:55,220 - httpcore.http11 - DEBUG - send_request_body.complete
2025-04-07 10:23:55,220 - httpcore.http11 - DEBUG - receive_response_headers.started request=<Request [b'POST']>
2025-04-07 10:23:55,858 - urllib3.connectionpool - DEBUG - https://api.smith.langchain.com:443 "POST /runs/multipart HTTP/1.1" 202 34
2025-04-07 10:23:59,882 - httpcore.http11 - DEBUG - receive_response_headers.complete return_value=(b'HTTP/1.1', 200, b'OK', [(b'Date', b'Mon, 07 Apr 2025 14:23:59 GMT'), (b'Content-Type', b'application/json'), (b'Transfer-Encoding', b'chunked'), (b'Connection', b'keep-alive'), (b'access-control-expose-headers', b'X-Request-ID'), (b'openai-organization', b'user-c4kmud4pram6lu62sxpadvux'), (b'openai-processing-ms', b'3573'), (b'openai-version', b'2020-10-01'), (b'x-ratelimit-limit-requests', b'5000'), (b'x-ratelimit-limit-tokens', b'800000'), (b'x-ratelimit-remaining-requests', b'4999'), (b'x-ratelimit-remaining-tokens', b'798471'), (b'x-ratelimit-reset-requests', b'12ms'), (b'x-ratelimit-reset-tokens', b'114ms'), (b'x-request-id', b'req_e7672537175d92f6ae7bc05c82237326'), (b'strict-transport-security', b'max-age=31536000; includeSubDomains; preload'), (b'cf-cache-status', b'DYNAMIC'), (b'X-Content-Type-Options', b'nosniff'), (b'Server', b'cloudflare'), (b'CF-RAY', b'92ca2f826c3ea1fe-YYZ'), (b'Content-Encoding', b'gzip'), (b'alt-svc', b'h3=":443"; ma=86400')])
2025-04-07 10:23:59,884 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2025-04-07 10:23:59,884 - httpcore.http11 - DEBUG - receive_response_body.started request=<Request [b'POST']>
2025-04-07 10:23:59,885 - httpcore.http11 - DEBUG - receive_response_body.complete
2025-04-07 10:23:59,885 - httpcore.http11 - DEBUG - response_closed.started
2025-04-07 10:23:59,885 - httpcore.http11 - DEBUG - response_closed.complete
2025-04-07 10:23:59,885 - openai._base_client - DEBUG - HTTP Response: POST https://api.openai.com/v1/chat/completions "200 OK" Headers({'date': 'Mon, 07 Apr 2025 14:23:59 GMT', 'content-type': 'application/json', 'transfer-encoding': 'chunked', 'connection': 'keep-alive', 'access-control-expose-headers': 'X-Request-ID', 'openai-organization': 'user-c4kmud4pram6lu62sxpadvux', 'openai-processing-ms': '3573', 'openai-version': '2020-10-01', 'x-ratelimit-limit-requests': '5000', 'x-ratelimit-limit-tokens': '800000', 'x-ratelimit-remaining-requests': '4999', 'x-ratelimit-remaining-tokens': '798471', 'x-ratelimit-reset-requests': '12ms', 'x-ratelimit-reset-tokens': '114ms', 'x-request-id': 'req_e7672537175d92f6ae7bc05c82237326', 'strict-transport-security': 'max-age=31536000; includeSubDomains; preload', 'cf-cache-status': 'DYNAMIC', 'x-content-type-options': 'nosniff', 'server': 'cloudflare', 'cf-ray': '92ca2f826c3ea1fe-YYZ', 'content-encoding': 'gzip', 'alt-svc': 'h3=":443"; ma=86400'})
2025-04-07 10:23:59,885 - openai._base_client - DEBUG - request_id: req_e7672537175d92f6ae7bc05c82237326
2025-04-07 10:24:00,049 - urllib3.connectionpool - DEBUG - https://api.smith.langchain.com:443 "POST /runs/multipart HTTP/1.1" 202 34
2025-04-07 10:24:00,076 - langsmith.client - DEBUG - Closing Client.session
2025-04-07 10:24:00,080 - langsmith.client - DEBUG - Closing Client.session
